Osteoarthritis

StrainsForPains, Inc. Discusses Inspiration, App Technology and CBD Market Entrance with The Stock Day Podcast

Retrieved on: 
Thursday, February 29, 2024

I financed and worked with Olivia Newton-John's Koala Blue in the 1980's and Richard Diehl's Graphsoft (now Vectorworks) in the 1990's.

Key Points: 
  • I financed and worked with Olivia Newton-John's Koala Blue in the 1980's and Richard Diehl's Graphsoft (now Vectorworks) in the 1990's.
  • I developed regenerative medicine systems with stem cell technology in the 1980's working on umbilical cord therapy to treat genetic diseases, cancers, and inherited disorders.
  • In 2024 we will focus our efforts on the development of our upcoming advanced AI app and our CBD brand that will expand into many products.
  • We will seek to forge a new path in our approach to healthcare, that will expand to CBD products for pets as well as a nutritional app.

New to The Street Announces its Five Corporate TV Interviews, Airing Episode 561 on the FOX Business Network Monday, March 11, 2024, at 10:30 PM PT

Retrieved on: 
Friday, March 8, 2024

NEW YORK, March 08, 2024 (GLOBE NEWSWIRE) -- FMW Media's New to The Street , a nationally broadcasted TV show, announces episode 561, airing on the FOX Business Network Monday, March 11, 2024, at 10:30 PM PT.

Key Points: 
  • NEW YORK, March 08, 2024 (GLOBE NEWSWIRE) -- FMW Media's New to The Street , a nationally broadcasted TV show, announces episode 561, airing on the FOX Business Network Monday, March 11, 2024, at 10:30 PM PT.
  • New to The Street's 561st TV episode line-up features the following five (5) Corporate interviews:
    1).
  • Veterinarians are increasingly using the product as an alternative to surgery, helping pet owners manage pets with osteoarthritis and other joint-related ailments.
  • First, in October 2023, veterinarians presented SPRYNG™'s positive study results on dogs with cranial cruciate ligament (CCL) disease.

New to The Street Announces TV Episode 560 with its Five Business Guest Interviews, Airs as Sponsored Programming on Bloomberg TV Tonight, Thursday, March 7, 2024, at 9:30 PM PT

Retrieved on: 
Thursday, March 7, 2024

First, in October 2023, veterinarians presented SPRYNG™'s positive study results on dogs with cranial cruciate ligament (CCL) disease.

Key Points: 
  • First, in October 2023, veterinarians presented SPRYNG™'s positive study results on dogs with cranial cruciate ligament (CCL) disease.
  • Also, Ethos Veterinary Health, LLC's study on canine hip dysplasia using the product shows success, giving more veterinary doctors information about product uses.
  • PETV's SPRYNG™ with OsteoCushion Technology is a "Game Changer" medical device that successfully treats pets and gives owners options beyond surgeries.
  • New to The Street airs TV Host Jane King's interview with VRM BioLogik® Group's (VRM) Ken Bellamy, Founder and President .

CytoMed Therapeutics Limited Announces Research Collaboration with Singapore Sengkang General Hospital to Advance Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Diseases and Repair

Retrieved on: 
Monday, March 4, 2024

Osteoarthritis of the knee is a debilitating disease affecting Singapore’s aging population and the clinical trial will pioneer stem cell use for regenerative medicine in Singapore.

Key Points: 
  • Osteoarthritis of the knee is a debilitating disease affecting Singapore’s aging population and the clinical trial will pioneer stem cell use for regenerative medicine in Singapore.
  • UC-MSCs are a type of adult stem cells that can be isolated from the umbilical cord tissue after childbirth.
  • UC-MSCs are considered multipotent and are able to differentiate into different cell types, including bone, cartilage, fat, and muscle cells.
  • "Our collaboration with CytoMed marks a significant step in advancing research on allogeneic in-vivo UC-MSC for cartilage repair, including osteoarthritis of the knee.

New to The Street Announces its Line-up, Four Corporate Interviews Airings on The FOX Business Network, Monday, March 4, 2024, at 10:30 PM PT

Retrieved on: 
Friday, March 1, 2024

NEW YORK, March 01, 2024 (GLOBE NEWSWIRE) -- FMW Media's New to The Street announces its 559th episode line-up, featuring four corporate interviews airing on the FOX Business Network on Monday, March 4, 2024, at 10:30 PM PT.

Key Points: 
  • Veterinarians are increasingly using the product as an alternative to surgery, helping pet owners manage pets with osteoarthritis and other joint-related ailments.
  • First, in October 2023, veterinarians presented SPRYNG™'s positive study results on dogs with cranial cruciate ligament (CCL) disease.
  • Also, Ethos Veterinary Health, LLC's study on canine hip dysplasia using the product shows success, giving more veterinary doctors information about product uses.
  • Viewers, please tune in next time for the newest cybersecurity topic on the "Sekur Privacy & Sekur Security– Weekly Hack" segment.

Clinical Study Results Involving Spryng, a PetVivo Holdings, Inc. Product, Presented at the Veterinary Orthopedic Society Annual Conference in Lake Tahoe, California

Retrieved on: 
Thursday, February 29, 2024

Spryng™ with OsteoCuhsion™ Technology) into the coxofemoral joint of dogs with osteoarthritis.

Key Points: 
  • Spryng™ with OsteoCuhsion™ Technology) into the coxofemoral joint of dogs with osteoarthritis.
  • The microparticles of Spryng have been found to adsorb onto the joint synovial lining of animals and subsequently integrate with the animal’s subsynovial tissue.
  • The dogs enrolled in this study had been diagnosed with unilateral or bilateral coxofemoral joint osteoarthritis.
  • To view the abstract of the clinical study presented at the VOS annual conference please visit the following:

ElleVet Academy Launches with Classes on Cannabinoid Veterinary Science, Offering Free RACE Approved CE Credits for Veterinary Professionals

Retrieved on: 
Thursday, February 15, 2024

PORTLAND, Maine, Feb. 15, 2024 /PRNewswire-PRWeb/ -- ElleVet Sciences, the leading authority on cannabinoid veterinary science, proudly announces the launch of ElleVet Academy (ellevetacademy.com), its online learning platform offering free continuing education (CE) credits to veterinary professionals. ElleVet Academy courses aim to empower veterinary professionals with the knowledge and skills needed to confidently incorporate cannabinoid-based products into their practice to support patients with osteoarthritis, epilepsy, atopic dermatitis, and anxiety.

Key Points: 
  • PORTLAND, Maine, Feb. 15, 2024 /PRNewswire-PRWeb/ -- ElleVet Sciences, the leading authority on cannabinoid veterinary science, proudly announces the launch of ElleVet Academy ( ellevetacademy.com ), its online learning platform offering free continuing education (CE) credits to veterinary professionals.
  • "ElleVet Academy represents a pivotal step in advancing veterinary education," said Dr. Joseph J. Wakshlag, Chief Veterinary Medical Officer, ElleVet Sciences.
  • Free Continuing Education Credits: Veterinary professionals can earn RACE-approved CE credits at no cost, making ElleVet Academy the most accessible and comprehensive resource for gaining essential education in cannabinoid veterinary science.
  • Scientific Expertise: ElleVet Academy courses were designed by the same veterinary professionals and researchers who brought cannabinoid veterinary science to the forefront of pet care.

BioElectronics Chairman Updates Investors

Retrieved on: 
Thursday, February 15, 2024

FREDERICK, MD, Feb. 15, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – BioElectronics Corporation (https://www.bielcorp.com/ OTC: BIEL a developer of medical technology products, today releases an update from its Chairman, Richard Staelin, PhD.

Key Points: 
  • FREDERICK, MD, Feb. 15, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – BioElectronics Corporation ( https://www.bielcorp.com/ OTC: BIEL a developer of medical technology products, today releases an update from its Chairman, Richard Staelin, PhD.
  • The intent of this short update is to provide potential investors and current stockholders as much information as possible on the progress of our Company over these last three months and our future plans.
  • Today, I will focus on the first of these, although I will briefly mention the two other vital components of our mission.
  • Such findings will be new to the literature and should provide important evidence on reducing opioid use and minimizing post-surgical chronic pain.

Ampio Provides Update on Results from Pre-IND Enabling Studies

Retrieved on: 
Wednesday, February 14, 2024

ENGLEWOOD, Colo., Feb. 14, 2024 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) (the "Company" or "Ampio"), a pre-revenue stage biopharmaceutical company focused on development of a potential treatment for osteoarthritis as part of its OA-201 program, today announced the efficacy results from recently completed nonclinical pre-IND enabling studies with OA-201, Ampio's only product development opportunity.

Key Points: 
  • ENGLEWOOD, Colo., Feb. 14, 2024 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) (the "Company" or "Ampio"), a pre-revenue stage biopharmaceutical company focused on development of a potential treatment for osteoarthritis as part of its OA-201 program, today announced the efficacy results from recently completed nonclinical pre-IND enabling studies with OA-201, Ampio's only product development opportunity.
  • Ampio reported that the efficacy results of these studies do not support an Investigational New Drug ("IND") submission which was anticipated in early 2025.
  • The Company's management and the Board are currently assessing both internal and external options.
  • The Company will be taking immediate actions to preserve its cash in order to be able to adequately fund any option identified by the Board.

New HSS Studies Highlight the Benefits of Robotic-Assisted Joint Replacement Surgery

Retrieved on: 
Wednesday, February 14, 2024

Investigators at HSS set out to determine if the use of computer navigation or robotic-arm assistance during surgery reduced the need for MUA.

Key Points: 
  • Investigators at HSS set out to determine if the use of computer navigation or robotic-arm assistance during surgery reduced the need for MUA.
  • "These results highlight the potential benefits of incorporating technological advancements into knee replacement surgery, offering improved outcomes and reducing the need for additional interventions such as MUA," Dr. Jerabek said.
  • The second study compared short-term outcomes of the anterior versus the posterior approach in robotic-assisted total hip replacement (THR) surgery.
  • "As the use of robotic assistance in joint replacement surgery becomes more common, future studies should evaluate outcomes over longer periods of time," concluded Dr. Mayman.